A phase 1 study of the BCL2-targeted deoxyribonucleic acid inhibitor (DNAi) PNT2258 in patients with advanced solid tumors

PURPOSE: Maximum tolerated dose, safety, pharmacokinetics, and pharmacodynamics were assessed in this phase 1 study of PNT2258, a BCL-2-targeted liposomal formulation of a 24-base DNA oligonucleotide called PNT100. METHODS: Patients with malignant solid tumors were assigned sequentially to one of te...

Full beskrivning

Sparad:
Bibliografiska uppgifter
Huvudupphovsmän: Tolcher, Anthony W., Rodrigueza, Wendi V., Rasco, Drew W., Patnaik, Amita, Papadopoulos, Kyriakos P., Amaya, Alex, Moore, Timothy D., Gaylor, Shari K., Bisgaier, Charles L., Sooch, Mina P., Woolliscroft, Michael J., Messmann, Richard A.
Materialtyp: Artigo
Språk:Inglês
Publicerad: Springer Berlin Heidelberg 2013
Ämnen:
Original Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC3909249/
https://ncbi.nlm.nih.gov/pubmed/24297683
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-013-2361-0
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk